Old Second National Bank Of Aurora Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Old Second National Bank Of Aurora reduced its stake in AbbVie Inc by 9.65% during the most recent quarter end. The investment management company now holds a total of 18,730 shares of AbbVie Inc which is valued at $1,150,397 after selling 2,000 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.AbbVie Inc makes up approximately 0.54% of Old Second National Bank Of Aurora’s portfolio.

AbbVie Inc closed down -0.23 points or -0.38% at $60.7 with 66,79,223 shares getting traded on Wednesday. Post opening the session at $60.93, the shares hit an intraday low of $60.25 and an intraday high of $61.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Thompson Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 47,423 additional shares and now holds a total of 70,642 shares of AbbVie Inc which is valued at $4,338,832. AbbVie Inc makes up approx 0.89% of Thompson Investment Management’s portfolio.Hartford Financial Management boosted its stake in ABBV in the latest quarter, The investment management firm added 79 additional shares and now holds a total of 979 shares of AbbVie Inc which is valued at $60,130. AbbVie Inc makes up approx 0.04% of Hartford Financial Management’s portfolio.Redwood Investments reduced its stake in ABBV by selling 249,086 shares or 99.96% in the most recent quarter. The Hedge Fund company now holds 100 shares of ABBV which is valued at $6,142.Davis R M Inc reduced its stake in ABBV by selling 1,013 shares or 3.62% in the most recent quarter. The Hedge Fund company now holds 27,007 shares of ABBV which is valued at $1,658,770. AbbVie Inc makes up approx 0.08% of Davis R M Inc’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.